Publicis Groupe Announcement

PARIS--(BUSINESS WIRE)-- Regulatory News:

Publicis Groupe (Paris: PUB) [Euronext Paris FR0000130577, CAC 40] announced today the resignation of Kevin Roberts Head Coach de Publicis Groupe, Executive Chairman of Saatchi & Saatchi/Fallon, Member of the Management Board.

The Supervisory Board and the Chairman and CEO of Publicis Groupe took note of Kevin Robert’s decision to step down with effect from September 1st 2016, prior to his retirement date due in May 2017.

About Publicis Groupe – The Power of OnePublicis Groupe [Euronext Paris FR0000130577, CAC 40] is a global leader in marketing, communication, and digital transformation. Active across the entire value chain, from consulting to creation, and production, Publicis Groupe offers its clients a transversal, unified and fluid model allowing them access to all the Groupe’s tools and expertise around the world. Publicis Groupe is organized across four Solutions hubs:Publicis Communications, Publicis Media, Publicis.Sapient and Publicis Health. These 4 Solutions hubs operate across principal markets, and are carried across all others by Publicis One. Publicis One is a fully integrated service offering making the Groupe’s expertise available to all clients, under one roof. Present in over 100 countries, Publicis Groupe employs nearly 80,000 professionals.www.publicisgroupe.com | Twitter: @PublicisGroupe | Facebook: www.facebook.com/publicisgroupe | LinkedIn: Publicis Groupe | http://www.youtube.com/user/PublicisGroupe | Viva la Difference!

View source version on businesswire.com: http://www.businesswire.com/news/home/20160803006038/en/

Publicis Groupe
Corporate Communications
Peggy Nahmany, + 33 (0)1 44 43 72 83
[email protected]
or
Investor Relations
Jean-Michel Bonamy, + 33 (0)1 44 43 77 88
[email protected]
or
Investor Relations
Chi-Chung Lo, + 33 (0)1 44 43 66 69
[email protected]

Source: Publicis Groupe

You May Also Be Interested In

• PreveCeutical closes second tranche of private placement for $245,000
• Marathon Petroleum Named to Dow Jones Best-in-Class Indices
• FDA approves Merck's KEYTRUDA and WELIREG combination for kidney cancer